65 In a meta-analysis by He et al, which included 76 RCTs covering more than 100,000 overweight or obese individuals, GLP-1 RA use was reported to increase the risk of gallbladder stones or biliary tract disease by 37% (RR 1.37 [95% CI 1.231.52])
While we do not ship or provide these branded products directly, we connect individuals with licensed providers who may prescribe compounded semaglutide or compounded tirzepatide
In late 2025, the federal government announced Medicare will cover anti-obesity medications starting in 2026 a game-changer for providers serving older adults
Vomiting and nausea can mess with any pill Here is the catch that applies no matter which GLP-1 you take
Gwnym przeciwwskazaniem w stosowaniu peptydu s istniejce choroby nowotworowe
Enter into Negotiations: Once the case is filed, the lawsuit may enter the Discovery phase